radiation therapy, chemotherapy, and targeted drug therapy. Medical management is often associated with the development of treatment resistance leading to relapse. Immunotherapy is profoundly altering the approach to cancer treatment owing to
The National Cancer Institute. Common terminology criteria for adverse events (CTCAE) Version 4.0 (2010). Bethesda: Approved after October 1, 2009. Wolf FJ, Grand DJ, Machan JT, Dipetrillo TA, Mayo-Smith WW, Dupuy DE. Microwave ablation of lung malignancies: effectiveness, CT findings, and ...
Lung cancer is the leading cause of cancer death in the United States and throughout the world.1 In the United States, the manufactured cigarette emerged as the tobacco product of choice shortly after the turn of the 20th century. Lung cancer surfaced after years of inhalation of cigarette sm...
Non-small cell lung cancerImmunotherapyToxicityLIPIPredictorSurvivalBackground Immune checkpoint inhibitors (ICIs) have been proposed as the standard first-line and subsequent treatment for metastatic non-small cell lung cancer (NSCLC). This study analyzed whether patients with good lung immune prognostic...
2 Assessment and classification of patients were performed under the National Cancer Institute Common Terminology for Adverse Events.3 “Patients with lung cancer undergoing chemoradiotherapy are at high risk of severe and potentially life-threatening esophagitis, including an inability to eat or swal...
Lung Cancer: Targets and Therapy 1 September 2014 Number of times this article has been viewed Sacha I Rothschild Department of Internal Medicine, Medical Oncology, University Hospital Basel, Basel, Switzerland Abstract: The therapeutic landscape in non-small-cell lung cancer (NSCLC) is changing. Th...
Cancer: A Chronic Pandemic David IlanSuster,MariMino-Kenudson, inArchives of Medical Research, 2020 Squamous Cell Carcinoma Lung SCC is the second most common subtype ofNSCLCand much likelung ADCis characterized by a complex molecular background which shares many of the same molecular features as...
EGFR exon 20 insertion (20ins)-positive non-small-cell lung cancer (NSCLC) is an uncommon disease with limited therapeutic options and dismal prognosis. Here we report the activity, tolerability, potential mechanisms of response and resistance for dual targeting EGFR 20ins with JMT101 (anti-EGFR...
A phase II trial of irinotecan and cisplatin (IP) as induction chemotherapy followed by conventional thoracic irradiation concurrent with low-dose weekly cisplatin for limited-disease small-cell lung cancer (LDS-SCLC). Between February 2005 and December 2008, 34 chemotherapy-naïve patients with LD...
Patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) often develop resistance to current standard third-generation EGFR tyrosine kinase inhibitors (TKIs); no targeted treatments are approved in the osimertinib-relapsed setting. In this open-label, dose-escal...